Novo Nordisk

#EASD26: Regeneron’s antibody helps patients regain muscle after stopping GLP-1 therapy Endpoints NewsThe Next Frontier for Obesity Drugs Isn’t…

Hundreds of Americans are suing GLP-1 drugmakers Novo Nordisk and Ely Lilly, saying they were not adequately warned…

Novo Sets Long-Term Targets Ahead of Semaglutide Patent Expirations Yahoo FinanceNovo shares slide as drugmaker lays out post-Wegovy growth…

Morgan Stanley has cut Novo Nordisk A/S (NYSE:NVO) to Underweight on September 11, 2026. Semaglutide, the underlying molecule…

The healthcare sector is shifting as legacy blockbusters face competition from low-cost generics while new chronic care treatments…

On August 5, Eli Lilly (NYSE:LLY) told investors its second quarter delivered 48% revenue growth, and the days…

New Delhi: The Delhi High Court on Tuesday asked Sun Pharma Laboratories to take its prior approval before…

This article first appeared on GuruFocus. Amazon.com Inc. (AMZN, Financials), the e-commerce and cloud-computing company, is expanding its…

Aug 6 (Reuters) – Amazon’s pharmacy unit said on Thursday it would offer weight-loss drugs to eligible Medicare…

Earnings continue to be the market’s engine, and a series of results this week from Palantir (PLTR), SpaceX…

A recent high-profile court judgment halting a Pretoria pharmacy from selling GLP-1 drugs at scale has seemingly done…

Investing.com — Eli Lilly announced Thursday it will file for approval of its next-generation obesity drug retatrutide in…

#EASD26: Regeneron’s antibody helps patients regain muscle after stopping GLP-1 therapy – Endpoints News